Kane Biotech revyve presented at MHSRS
Analysis based on 7 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026
The announcement is a positive development for Kane Biotech, potentially expanding its market into military and government healthcare channels. However, the stock closed at $0.03 without movement, indicating limited immediate market reaction.
Kane Biotech Inc. announced that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS) held August 3-5, 2026 in Kissimmee, Florida. The presentation, authored by Kane Biotech's Drs. Huizinga, Sailer and Visvalingam, was presented by Lt. Col. Steven Jeffery, a consultant plastic surgeon and professor at Birmingham City University. The presentation focused on the potential application of revyve Antimicrobial Wound Gel Spray in military and prolonged field care settings, particularly in austere environments. Following the presentation, several researchers approached Kane to explore potential applications, and Kane is working with them to develop a clinical research plan. Kane continues to advance commercialization of its revyve portfolio, which includes FDA 510(k) cleared and Canada — Health Canada approved products. The company believes military and government healthcare channels may represent a long-term opportunity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard